AstraZeneca's breast cancer pill camizestrant fails to improve progression-free survival in pivotal SERENA-4 trial

AstraZeneca announced that its oral estrogen receptor degrader camizestrant, marketed as Etcamah, did not meet its primary endpoint in the phase III SERENA-4 trial.

The study evaluated camizestrant combined with standard therapy as a first-line treatment for patients with ER-positive, HER2-negative advanced breast cancer who had not received prior systemic therapy for advanced disease. The combination failed to show a statistically significant improvement in progression-free survival compared with standard treatment.

Camizestrant had received accelerated approval in the United States earlier this month for patients whose tumors harbor a specific resistance-associated mutation. The negative readout limits the drug’s potential to expand beyond that niche indication.

AstraZeneca said it will continue to investigate camizestrant in earlier-stage disease settings, but the setback may curb expectations for a broader market opportunity.